Keros Therapeutics (NASDAQ:KROS) Trading Down 8.9% - Here's What Happened

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) traded down 8.9% on Monday . The company traded as low as $13.07 and last traded at $13.26. 220,614 shares were traded during trading, a decline of 72% from the average session volume of 795,165 shares. The stock had previously closed at $14.56.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on KROS shares. HC Wainwright reduced their target price on shares of Keros Therapeutics from $100.00 to $47.00 and set a "buy" rating for the company in a report on Friday, December 13th. Wells Fargo & Company increased their price objective on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 11th. Wedbush restated an "outperform" rating and set a $84.00 target price on shares of Keros Therapeutics in a research note on Thursday, November 7th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Finally, BTIG Research cut Keros Therapeutics from a "buy" rating to a "neutral" rating in a report on Thursday, December 12th. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat, Keros Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $75.00.

Keros Therapeutics Stock Down 16.5 %

The stock has a market capitalization of $422.08 million, a P/E ratio of -2.00 and a beta of 1.43. The company has a fifty day moving average price of $39.77 and a 200-day moving average price of $47.88.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $0.39 million for the quarter. During the same period in the previous year, the company earned ($1.33) EPS. Keros Therapeutics's quarterly revenue was up 4750.0% compared to the same quarter last year. As a group, research analysts expect that Keros Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

Large investors have recently bought and sold shares of the business. KBC Group NV lifted its position in Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company's stock valued at $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock valued at $77,000 after buying an additional 280 shares in the last quarter. Values First Advisors Inc. purchased a new position in Keros Therapeutics in the third quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Keros Therapeutics in the second quarter worth about $128,000. Finally, LMR Partners LLP bought a new stake in Keros Therapeutics during the third quarter worth approximately $213,000. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.